Worldwide emergence of extensively drug-resistant tuberculosis

N. Sarita Shah; Abigail Wright; Gill Han Bai; Lucia Barrera; Fadila Boulahbal; Nuria Martín-Casabona; Francis Drobniewski; Chris Gilpin; Marta Havelková; Rosario Lepe; Richard Lumb; Beverly Metchock; Françoise Portaels; Maria Filomena Rodrigues; Sabine Rüsch-Gerdes; Armand Van Deun; Veronique Vincent; Kayla Laserson; Charles Wells; J. Peter Cegielski

doi:10.3201/eid1303.061400

Worldwide emergence of extensively drug-resistant tuberculosis

N. Sarita Shah^*, Abigail Wright, Gill Han Bai, Lucia Barrera, Fadila Boulahbal, Nuria Martín-Casabona, Francis Drobniewski, Chris Gilpin, Marta Havelková, Rosario Lepe, Richard Lumb, Beverly Metchock, Françoise Portaels, Maria Filomena Rodrigues, Sabine Rüsch-Gerdes, Armand Van Deun, Veronique Vincent, Kayla Laserson, Charles Wells, J. Peter Cegielski

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

465 Citations (Scopus)

Abstract

Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000-2004. We defined extensively drug-resistant TB (XDR TB) as MDR TB with further resistance to ≥3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for XDR TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR TB are crucial for protection of public health and control of TB.

Original language	English
Pages (from-to)	380-387
Number of pages	8
Journal	Emerging Infectious Diseases
Volume	13
Issue number	3
DOIs	https://doi.org/10.3201/eid1303.061400
Publication status	Published - Mar 2007

Bibliographical note

Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3201/eid1303.061400

Cite this

Shah, N. S., Wright, A., Bai, G. H., Barrera, L., Boulahbal, F., Martín-Casabona, N., Drobniewski, F., Gilpin, C., Havelková, M., Lepe, R., Lumb, R., Metchock, B., Portaels, F., Rodrigues, M. F., Rüsch-Gerdes, S., Van Deun, A., Vincent, V., Laserson, K., Wells, C., & Cegielski, J. P. (2007). Worldwide emergence of extensively drug-resistant tuberculosis. Emerging Infectious Diseases, 13(3), 380-387. https://doi.org/10.3201/eid1303.061400

@article{b9d7381fc97a43a289b5558a2ca4554a,

title = "Worldwide emergence of extensively drug-resistant tuberculosis",

abstract = "Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000-2004. We defined extensively drug-resistant TB (XDR TB) as MDR TB with further resistance to ≥3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for XDR TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR TB are crucial for protection of public health and control of TB.",

author = "Shah, {N. Sarita} and Abigail Wright and Bai, {Gill Han} and Lucia Barrera and Fadila Boulahbal and Nuria Mart{\'i}n-Casabona and Francis Drobniewski and Chris Gilpin and Marta Havelkov{\'a} and Rosario Lepe and Richard Lumb and Beverly Metchock and Fran{\c c}oise Portaels and Rodrigues, {Maria Filomena} and Sabine R{\"u}sch-Gerdes and {Van Deun}, Armand and Veronique Vincent and Kayla Laserson and Charles Wells and Cegielski, {J. Peter}",

year = "2007",

month = mar,

doi = "10.3201/eid1303.061400",

language = "English",

volume = "13",

pages = "380--387",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "3",

}

Shah, NS, Wright, A, Bai, GH, Barrera, L, Boulahbal, F, Martín-Casabona, N, Drobniewski, F, Gilpin, C, Havelková, M, Lepe, R, Lumb, R, Metchock, B, Portaels, F, Rodrigues, MF, Rüsch-Gerdes, S, Van Deun, A, Vincent, V, Laserson, K, Wells, C & Cegielski, JP 2007, 'Worldwide emergence of extensively drug-resistant tuberculosis', Emerging Infectious Diseases, vol. 13, no. 3, pp. 380-387. https://doi.org/10.3201/eid1303.061400

TY - JOUR

T1 - Worldwide emergence of extensively drug-resistant tuberculosis

AU - Shah, N. Sarita

AU - Wright, Abigail

AU - Bai, Gill Han

AU - Barrera, Lucia

AU - Boulahbal, Fadila

AU - Martín-Casabona, Nuria

AU - Drobniewski, Francis

AU - Gilpin, Chris

AU - Havelková, Marta

AU - Lepe, Rosario

AU - Lumb, Richard

AU - Metchock, Beverly

AU - Portaels, Françoise

AU - Rodrigues, Maria Filomena

AU - Rüsch-Gerdes, Sabine

AU - Van Deun, Armand

AU - Vincent, Veronique

AU - Laserson, Kayla

AU - Wells, Charles

AU - Cegielski, J. Peter

PY - 2007/3

Y1 - 2007/3

N2 - Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000-2004. We defined extensively drug-resistant TB (XDR TB) as MDR TB with further resistance to ≥3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for XDR TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR TB are crucial for protection of public health and control of TB.

AB - Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000-2004. We defined extensively drug-resistant TB (XDR TB) as MDR TB with further resistance to ≥3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for XDR TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR TB are crucial for protection of public health and control of TB.

UR - http://www.scopus.com/inward/record.url?scp=33847414693&partnerID=8YFLogxK

U2 - 10.3201/eid1303.061400

DO - 10.3201/eid1303.061400

M3 - Article

C2 - 17552090

AN - SCOPUS:33847414693

SN - 1080-6040

VL - 13

SP - 380

EP - 387

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 3

ER -

Worldwide emergence of extensively drug-resistant tuberculosis

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this